This inventor holds 1 USPTO granted patent. Top assignee: Merck Patent Gesellschaft MIT Beschrankter Haftung. Active years: 1998.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1998
Title: Martin Wild - Innovator in Tumor Therapy
Introduction
Martin Wild is a prominent inventor based in Heidelberg, Germany. He has made significant contributions to the field of tumor therapy through his innovative research and development of bispecific antibody fragments.
Latest Patents
Wild holds a patent for bispecific molecules that recognize lymphocyte antigen CD2 and tumor antigens. This invention relates to novel and highly effective bispecific antibody fragments that can be utilized in tumor therapy and diagnostics. His patent includes two new monoclonal antibodies, AICD2.M1 and AICD2.M2, which can be combined for enhanced therapeutic effects.
Career Highlights
Martin Wild is associated with Merck Patent Gesellschaft mit beschränkter Haftung, where he continues to advance his research in immunotherapy. His work focuses on developing innovative solutions for cancer treatment, showcasing his commitment to improving patient outcomes.
Collaborations
Wild collaborates with esteemed colleagues such as Stefan Meuer and Carlota-Silvia Jaggle, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Martin Wild's contributions to the field of tumor therapy through his patented inventions highlight his role as a leading inventor in the medical research community. His work continues to pave the way for advancements in cancer treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile